Epidyolex 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0025/G 
This was an application for a group of variations. 
01/06/2023 
n/a 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.d.1.f - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
A.7 - Administrative change - Deletion of 
manufacturing sites 
T/0026 
Transfer of Marketing Authorisation 
15/05/2023 
31/05/2023 
SmPC, 
Labelling and 
PL 
II/0020 
C.I.6.a - Change(s) to therapeutic indication(s) - 
26/04/2023 
SmPC and PL 
Addition of a new therapeutic indication or 
modification of an approved one 
IB/0024/G 
This was an application for a group of variations. 
21/02/2023 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.c.1.a - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.z - Change in control of the AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
IB/0023 
B.II.e.5.a.2 - Change in pack size of the finished 
02/02/2023 
31/05/2023 
SmPC, 
Product information updated to add a new pack-size of 3 x 
product - Change in the number of units (e.g. 
Labelling and 
100 ml bottles for Epidyolex 100 mg/ml oral solution 
tablets, ampoules, etc.) in a pack - Change outside 
PL 
(EU/1/19/1389/002). 
the range of the currently approved pack sizes 
PSUSA/10798
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
cannabidiol (for centrally authorised products only) 
N/0021 
Minor change in labelling or package leaflet not 
22/09/2022 
31/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0019 
B.z - Quality Change - Other variation 
19/04/2022 
n/a 
IB/0018/G 
This was an application for a group of variations. 
21/02/2022 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0016 
Update of section 5.3 of the SmPC to reflect the 
27/01/2022 
29/06/2022 
SmPC 
Update of section 5.3 of the SmPC to reflect the conclusions 
conclusions of the study GWTX1504, 104 week oral 
(gavage) administration carcinogenicity study in 
mouse. 
of the study GWTX1504, 104 week oral (gavage) 
administration carcinogenicity study in mouse. 
Page 4/10 
 
 
 
 
 
 
For more information, please refer to the Summary 
of Product Characteristics. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0015 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
27/01/2022 
29/06/2022 
SmPC 
Update of sections 4.5 and 5.2 of the SmPC to add drug-
new quality, preclinical, clinical or pharmacovigilance 
drug interaction information with everolimus and P-gp 
data 
substrates following the assessment the study GWCP19195, 
a phase I open-label pharmacokinetic drug-drug interaction 
trial to investigate the effect of cannabidiol on the 
pharmacokinetics of everolimus in healthy subject. In 
addition, the MAH took the opportunity to introduce 
editorial updates in section 5.1 and section 4.9 and to 
update the local representative contact details of France in 
the Package Leaflet. 
PSUSA/10798
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
cannabidiol (for centrally authorised products only) 
II/0014/G 
This was an application for a group of variations. 
14/10/2021 
n/a 
B.II.d.1.f - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10798
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
/202012 
cannabidiol (for centrally authorised products only) 
II/0007 
Update of sections 4.2 and 6.6 of the SmPC in order 
24/06/2021 
29/06/2022 
SmPC and PL 
to add information regarding enteral administration 
using nasogastric and gastrostomy tubes. The 
Package Leaflet is updated accordingly. In addition, 
the marketing authorisation holder has taken the 
opportunity to update the list of local representatives 
in the PL and implement minor editorial changes. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0005 
Extension of Indication for use as adjunctive therapy 
25/02/2021 
16/04/2021 
SmPC and PL 
Please refer to Scientific Discussion ‘Product Name-H-C-
of seizures associated with tuberous sclerosis 
complex (TSC) for patients 2 years of age and older. 
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 
5.1, 5.2 and 5.3 of the SmPC are updated. The 
Package Leaflet is updated accordingly. The updated 
RMP version 2.0 is agreed. 
The MAH also took the opportunity to correct 
typographic errors and implement editorial updates 
as well as implement the updated ethanol statement 
in compliance with the EC Guideline on Excipient. In 
addition, the list of local representatives in the PL 
has been revised to amend contact details for the 
representative(s) of Sweden. 
The variation leads to amendments to the Summary 
of Product Characteristics and Package Leaflet and to 
Product Number-II-0005’ 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
the Risk Management Plan (RMP). 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IA/0012/G 
This was an application for a group of variations. 
17/02/2021 
16/04/2021 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0011/G 
This was an application for a group of variations. 
05/02/2021 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IB/0010 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
01/02/2021 
16/04/2021 
SmPC, 
life of the finished product - After first opening 
Labelling and 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(supported by real time data) 
PL 
PSUSA/10798
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
cannabidiol (for centrally authorised products only) 
II/0008/G 
This was an application for a group of variations. 
23/07/2020 
09/12/2020 
SmPC 
Following the drug-drug interaction study GWEP17074 with 
Update of section 4.5 of the SmPC to reflect the data 
of the rifampicin drug-drug interaction study 
GWEP17074. 
rifampicin (CYP3A4 Inducer), section 4.5 of the SmPC has 
been updated to reflect the decrease plasma concentrations 
of cannabidiol and 7-hydroxy-cannabidiol by approximately 
30 and 60% respectively and potential impact on 
Update of section 4.5 of the SmPC to reflect the data 
effectiveness.  
of the CYP1A2 substrate (caffeine) drug-drug 
interaction study GWCP18056.  
Update of section 4.5 and 5.2 of the SmPC to 
propose an additional statement regarding the 
stiripentol interaction based on the pharmacological 
study GWEP1447 (provided in eCTD sequence 018, 
P46 006).  
Update of section 5.2 of the SmPC to reflect the data 
of the pharmacokinetic study GWEP17076, exploring 
the impact of meal, milk and alcohol on cannabidiol 
exposure.  
In addition, the MAH took the opportunity to correct 
the MAH address in the SmPC. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Following the pharmacokinetic study GWEP17076, section 
5.2 of the SmPC has been updated to reflect the effect of 
low-fat/low-calorie meal, bovine milk and alcohol on 
cannabidiol exposure. 
Following the drug-drug interaction study GWCP18056 with 
caffeine (CYP1A2 Substrate), section 4.5 of the SmPC has 
been updated to reflect the observed increased in caffeine 
exposure and recommend the monitoring of patients. 
Following the drug-drug interaction study GWEP1447 with 
stiripentol and valproate, the statement in section 4.5 of 
the SmPC has been adjusted to reflect the data. 
For more information, please refer to the Summary of 
Product Characteristics 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10798
Periodic Safety Update EU Single assessment - 
09/07/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
cannabidiol (for centrally authorised products only) 
IA/0006 
B.I.b.2.a - Change in test procedure for AS or 
11/05/2020 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0003/G 
This was an application for a group of variations. 
25/03/2020 
n/a 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IAIN/0002/G 
This was an application for a group of variations. 
16/12/2019 
09/12/2020 
SmPC, Annex 
II and PL 
B.II.b.2.c.2 - Change to importer, batch release 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0001/G 
This was an application for a group of variations. 
27/11/2019 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
